BLU.TO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Jun 2023 @ 16:00):

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications...

Stats
Today's Volume	28 666.00
Average Volume	69 410.00
Market Cap	2.47B
EPS	$0 ( 2024-03-19 )
Next earnings date	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.29
ATR14	$0.192 (0.99%)

Volume Correlation

Long: 0.09 (neutral)

Short: 0.55 (weak)

Signal:(58.517) Neutral

BELLUS Health Inc Correlation

10 Most Positive Correlations
WE.V	0.959
MAW.TO	0.951
ABST.TO	0.951
FSY.TO	0.921
URB.TO	0.919
HURA.TO	0.899
SNC.TO	0.895
URE.TO	0.894
NXE.TO	0.892
APL.V	0.885

10 Most Negative Correlations
IVQ.TO	-0.93
IVX.V	-0.928
FTN.TO	-0.899
SIS.TO	-0.897
ME.TO	-0.894
CFF.TO	-0.894
AOT.TO	-0.893
NA.TO	-0.886
MTL.TO	-0.881
PLRB.V	-0.879

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BELLUS Health Inc Correlation - Currency/Commodity

0.64
( weak )

0.58
( weak )

0.75
( moderate )

-0.65
( moderate negative )

-0.66
( moderate negative )

-0.36
( neutral )

BELLUS Health Inc Financials

Annual	2022
Revenue:	$16 000.00
Gross Profit:	$16 000.00 (100.00 %)
EPS:	$-0.660

Q1	2023
Revenue:	$3 000.00
Gross Profit:	$3 000.00 (100.00 %)
EPS:	$-0.200

Q4	2022
Revenue:	$4 000.00
Gross Profit:	$4 000.00 (100.00 %)
EPS:	$-0.160

Q3	2022
Revenue:	$4 000.00
Gross Profit:	$4 000.00 (100.00 %)
EPS:	$-0.200

Financial Reports:

No articles found.

BELLUS Health Inc

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.